Washington University School of Medicine in St. Louis | Strategic Alliance Partners

Latest from Washington University School of Medicine in St. Louis


Zanubrutinib Showcases Superior PFS Benefit Over BR in Treatment-Naïve CLL/SLL, Including High-Risk Subsets

July 20, 2022

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.

Uproleselan Plus Chemotherapy Continues to Show Promise in AML

March 17, 2022

The addition of uproleselan to standard chemotherapy improved improve response rates and reduced chemotherapy-induced mucositis in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia in a phase 1/2 trial.

Increasing Treatment Pathways Pave the Way for Heartening Future Throughout Hematologic Malignancies

March 09, 2022

Stephen Oh, MD, PhD, discusses current and emerging agents in myelofibrosis, advances in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, updates in acute and chronic graft-vs-host-disease, and chronic lymphocytic leukemia management.

Afami-cel Shows Clinical Benefit in Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

February 07, 2022

Brian A. Van Tine, MD, PhD, sheds light on the promise of SPEAR T-cell therapy in patients with synovial sarcoma and MRCLS, the safety and efficacy observed with afami-cel in the SPEARHEAD-1 trial, and next steps for research.

Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

May 04, 2021

The addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow transplantation in up to 2 apheresis sessions vs G-CSF alone in patients with multiple myeloma, meeting the primary end point of the phase 3 GENESIS trial.